2023 World Conference on Lung Cancer (Posters)-EP12.01. Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases

EP12.01. Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases - PDF(Slides)

Back to course

Pdf Summary

A case study conducted by Qingqing Zhu at The First Affiliated Hospital of Anhui Medical University in China explored the use of high-dose aumolertinib in treating non-small cell lung cancer (NSCLC) patients with brain metastases after local progression. Aumolertinib is a novel third-generation EGFR-TKI that has better penetration in the central nervous system (CNS) compared to previous generations. Clinical trials have shown that aumolertinib has an acceptable safety profile.<br /><br />The study followed a 46-year-old female patient with stage IVB NSCLC. The patient had multiple pulmonary nodules, malignant pleural effusion, and brain metastases. She received various treatments, including Endostar and cisplatin, before receiving the definite next-generation sequencing (NGS) results, which showed an EGFR mutation. The patient was then treated with 110mg of aumolertinib.<br /><br />Regular follow-up showed significant shrinkage of the tumor. The best response was a partial response (PR) with a progression-free survival of 17 months. However, tumor progression was observed at the primary lung lesion after 17 months of aumolertinib treatment. Nonetheless, the patient demonstrated an excellent overall response, including complete response (CR), in multiple brain metastases after two months of treatment.<br /><br />The patient continued to receive treatment with aumolertinib, with the dose increased to 165mg. The patient tolerated the higher dose well and showed stable lung lesion and complete response in brain metastases. The second progression-free survival was over 16 months, and the patient responded well to aumolertinib with no significant adverse events.<br /><br />Overall, the study suggests that high-dose aumolertinib can be well tolerated and has prolonged efficacy in NSCLC patients with brain metastasis after local progression with the standard dose. It provides an optional strategy for these patients. Aumolertinib's better CNS penetration and acceptable safety profile make it a potential treatment option for this patient population.

Asset Subtitle

Qingqing Zhu

Meta Tag

Speaker Qingqing Zhu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

high-dose aumolertinib

non-small cell lung cancer

NSCLC

brain metastases

local progression

EGFR-TKI

central nervous system

clinical trials

progression-free survival

next-generation sequencing